Melvin M. Evers

2.1k total citations
39 papers, 1.6k citations indexed

About

Melvin M. Evers is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Genetics. According to data from OpenAlex, Melvin M. Evers has authored 39 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 23 papers in Cellular and Molecular Neuroscience and 5 papers in Genetics. Recurrent topics in Melvin M. Evers's work include Genetic Neurodegenerative Diseases (23 papers), Mitochondrial Function and Pathology (12 papers) and Muscle Physiology and Disorders (10 papers). Melvin M. Evers is often cited by papers focused on Genetic Neurodegenerative Diseases (23 papers), Mitochondrial Function and Pathology (12 papers) and Muscle Physiology and Disorders (10 papers). Melvin M. Evers collaborates with scholars based in Netherlands, Italy and Canada. Melvin M. Evers's co-authors include Willeke van Roon‐Mom, Lodewijk J.A. Toonen, Pavlina Konstantinova, S J van Deventer, Jana Miniarikova, Martin B. Rook, Marti F.A. Bierhuizen, Marc A. Vos, Harald Petry and Cynthia Brouwers and has published in prestigious journals such as Nucleic Acids Research, PLoS ONE and Brain.

In The Last Decade

Melvin M. Evers

39 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Melvin M. Evers Netherlands 22 1.3k 671 264 216 207 39 1.6k
Masayuki Nakamori Japan 31 2.6k 2.1× 1.8k 2.7× 451 1.7× 190 0.9× 202 1.0× 92 3.2k
Takao Honda Japan 15 510 0.4× 308 0.5× 109 0.4× 372 1.7× 75 0.4× 24 1.1k
Nobutada Tachi Japan 16 789 0.6× 619 0.9× 234 0.9× 150 0.7× 58 0.3× 86 1.3k
Liqun Liu‐Yesucevitz United States 6 1.3k 1.0× 266 0.4× 512 1.9× 68 0.3× 307 1.5× 7 1.6k
Francesco Lotti United States 21 1.9k 1.5× 211 0.3× 202 0.8× 204 0.9× 1.3k 6.3× 36 2.3k
Alex Mas Monteys United States 14 1.4k 1.1× 460 0.7× 125 0.5× 270 1.3× 49 0.2× 18 1.7k
Judit Herreros Spain 21 1.1k 0.9× 603 0.9× 385 1.5× 164 0.8× 81 0.4× 39 1.7k
Paulo A. Ferreira United States 24 1.4k 1.1× 223 0.3× 93 0.4× 261 1.2× 50 0.2× 45 1.6k
Jolanta Szulc Switzerland 8 993 0.8× 151 0.2× 168 0.6× 420 1.9× 145 0.7× 8 1.3k
Curtis M. Chan United States 7 990 0.8× 219 0.3× 121 0.5× 717 3.3× 353 1.7× 10 1.5k

Countries citing papers authored by Melvin M. Evers

Since Specialization
Citations

This map shows the geographic impact of Melvin M. Evers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melvin M. Evers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melvin M. Evers more than expected).

Fields of papers citing papers by Melvin M. Evers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melvin M. Evers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melvin M. Evers. The network helps show where Melvin M. Evers may publish in the future.

Co-authorship network of co-authors of Melvin M. Evers

This figure shows the co-authorship network connecting the top 25 collaborators of Melvin M. Evers. A scholar is included among the top collaborators of Melvin M. Evers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melvin M. Evers. Melvin M. Evers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Landles, Christian, Nicholas S. Caron, Georgina F Osborne, et al.. (2024). Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington's disease models. Brain. 147(12). 4043–4055. 9 indexed citations
2.
Nobre, Rui Jorge, Sónia Duarte, Sara Lopes, et al.. (2021). miRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3. Nucleic Acid Therapeutics. 32(3). 194–205. 13 indexed citations
3.
Pouw, Stephan M., Jiřı́ Klı́ma, Zdeňka Ellederová, et al.. (2021). Transduction profiles in minipig following MRI guided delivery of AAV-5 into thalamic and corona radiata areas. Journal of Neuroscience Methods. 365. 109382–109382. 1 indexed citations
4.
Miniarikova, Jana, et al.. (2020). Transfer of Therapeutic miRNAs Within Extracellular Vesicles Secreted from Huntington’s Disease iPSC-derived Neurons (4548). Neurology. 94(15_supplement). 4 indexed citations
5.
Heine, Vivi M., Pavlina Konstantinova, S J van Deventer, et al.. (2020). Cerebral Organoids: A Human Model for AAV Capsid Selection and Therapeutic Transgene Efficacy in the Brain. Molecular Therapy — Methods & Clinical Development. 18. 167–175. 26 indexed citations
6.
Martier, Raygene, Jolanda M.P. Liefhebber, Ana Garcı́a-Osta, et al.. (2019). Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. Molecular Therapy — Nucleic Acids. 16. 26–37. 76 indexed citations
7.
Martier, Raygene, Jeannette Hübener‐Schmid, Jiřı́ Klı́ma, et al.. (2019). Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease. Molecular Therapy — Methods & Clinical Development. 15. 343–358. 35 indexed citations
8.
Martier, Raygene, Jolanda M.P. Liefhebber, Jana Miniarikova, et al.. (2019). Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Molecular Therapy — Nucleic Acids. 14. 593–608. 47 indexed citations
9.
Brouwers, Cynthia, Astrid Vallès, Martin de Haan, et al.. (2019). AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models. Molecular Therapy — Methods & Clinical Development. 13. 334–343. 54 indexed citations
10.
Evers, Melvin M., Jana Miniarikova, Štefan Juhás, et al.. (2018). AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington’s Disease Minipig Model. Molecular Therapy. 26(9). 2163–2177. 122 indexed citations
11.
Toonen, Lodewijk J.A., Maurice Overzier, Melvin M. Evers, et al.. (2018). Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model. Molecular Neurodegeneration. 13(1). 31–31. 60 indexed citations
12.
Miniarikova, Jana, Melvin M. Evers, & Pavlina Konstantinova. (2018). Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic. Molecular Therapy. 26(4). 947–962. 36 indexed citations
13.
Miniarikova, Jana, Raygene Martier, Cynthia Brouwers, et al.. (2017). AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease. Gene Therapy. 24(10). 630–639. 80 indexed citations
14.
Toonen, Lodewijk J.A., et al.. (2016). In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington’s disease. Biomedicine & Pharmacotherapy. 84. 93–96. 8 indexed citations
15.
Evers, Melvin M., Lodewijk J.A. Toonen, & Willeke van Roon‐Mom. (2015). Antisense oligonucleotides in therapy for neurodegenerative disorders. Advanced Drug Delivery Reviews. 87. 90–103. 230 indexed citations
16.
Evers, Melvin M., Lodewijk J.A. Toonen, & Willeke van Roon‐Mom. (2013). Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies. Molecular Neurobiology. 49(3). 1513–31. 69 indexed citations
17.
Evers, Melvin M., Ioannis Zalachoras, Barry A. Pepers, et al.. (2013). Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: Removal of the CAG containing exon. Neurobiology of Disease. 58. 49–56. 60 indexed citations
18.
Zalachoras, Ioannis, Melvin M. Evers, Willeke van Roon‐Mom, Annemieke Aartsma‐Rus, & Onno C. Meijer. (2011). Antisense-Mediated RNA Targeting: Versatile and Expedient Genetic Manipulation in the Brain. Frontiers in Molecular Neuroscience. 4. 10–10. 17 indexed citations
19.
Evers, Melvin M., Barry A. Pepers, J.C.T. van Deutekom, et al.. (2011). Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide. PLoS ONE. 6(9). e24308–e24308. 78 indexed citations
20.
Vlijmen, Thijs van, Mathijs Vleugel, Melvin M. Evers, et al.. (2008). A unique residue in rab3c determines the interaction with novel binding protein Zwint‐1. FEBS Letters. 582(19). 2838–2842. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masayuki Nakamori Breakdown of academic impact, for papers by Takao Honda Breakdown of academic impact, for papers by Nobutada Tachi Breakdown of academic impact, for papers by Liqun Liu‐Yesucevitz Breakdown of academic impact, for papers by Francesco Lotti Breakdown of academic impact, for papers by Alex Mas Monteys Breakdown of academic impact, for papers by Judit Herreros Breakdown of academic impact, for papers by Paulo A. Ferreira Breakdown of academic impact, for papers by Jolanta Szulc Breakdown of academic impact, for papers by Curtis M. Chan
Rankless by CCL
2026